[Form 4] Niagen Bioscience, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Niagen Bioscience (NAGE) Director Kristin Patrick received a stock option grant for 20,000 shares of common stock on June 24, 2025. The options were granted with the following terms:

• Exercise price set at $14.13 per share
• 100% vesting scheduled for June 24, 2026
• Options expire on June 23, 2035
• Total grant value will be determined by stock price appreciation above $14.13

The Form 4 filing was signed by Attorney-in-Fact Jeong James Lee on June 26, 2025. This equity compensation grant appears to be part of the company's director compensation program, providing long-term alignment with shareholder interests through a 10-year exercise window following the one-year cliff vesting period.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patrick Kristin

(Last) (First) (Middle)

10900 WILSHIRE BLVD. SUITE 600

(Street)

LOS ANGELES CA 90024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Niagen Bioscience, Inc. [ NAGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.13	06/24/2025		A		20,000		06/24/2026(1)	06/23/2035	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Option vests 100% on June 24, 2026.

Remarks:

	/s/ Jeong James Lee, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did NAGE director Kristin Patrick receive on June 24, 2025?

According to the Form 4 filing, NAGE director Kristin Patrick received 20,000 stock options with an exercise price of $14.13 per share. These options were granted on June 24, 2025, will vest 100% on June 24, 2026, and expire on June 23, 2035.

When do Kristin Patrick's NAGE stock options vest?

The stock options granted to Kristin Patrick will vest 100% on June 24, 2026, as indicated in the Form 4 filing's explanatory notes.

What is the exercise price of NAGE stock options granted to director Kristin Patrick?

The stock options were granted with an exercise price of $14.13 per share, as reported in the Form 4 filing dated June 28, 2025.

How many NAGE stock options does Kristin Patrick beneficially own after the June 24, 2025 grant?

Following the reported transaction, Kristin Patrick beneficially owns 20,000 stock options of NAGE directly (indicated by 'D' in the ownership form column).

What position does Kristin Patrick hold at NAGE?

According to the Form 4 filing, Kristin Patrick serves as a Director of Niagen Bioscience, Inc. (NAGE), as indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.